Lawrence Solomon, M.D., Chairman, founder and Chief Executive Officer of ABP stated: "The Company is very pleased with the success of this Offering. ABP's goal is to see the ACCU-BREAK(TM) technologies become widely used within the pharmaceutical industry; achieving this goal could provide outstanding returns to shareholders."
ABP is developing the patent-pending ACCU-BREAK technologies for pharmaceutical tablets. The Company believes that these technologies may allow physicians to better customize treatment for their patients and that ACCU-BREAK tablets, if and when marketed, could represent improved dosage forms for many types of medications.
ABP is located at 1000 S. Pine Island Road, Suite 230, Plantation, FL 33324. Its website is www.accubreak.com.
ABP Disclosure Notice: This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "should," "would," "estimate," or "continue," or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Shareholders are cautioned that all forward-looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company's ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company's control. No ACCU-BREAK tablets have been marketed.
Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.
Contact: ACCU-BREAK Pharmaceuticals, Inc., Plantation Elliot F. Hahn, Ph.D., President, 954-236-7351 Fax: 954-236-7271 E.Hahn@accubreak.com
Source: ACCU-BREAK Pharmaceuticals, Inc.